Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New imaging study aims to personalize radiation therapy for GEP-NETs

NCT ID NCT06256705

First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 30 times

Summary

This study is looking at people with a rare type of tumor called GEP-NET that has spread and is growing. Participants will get special PET-MRI scans before, during, and after a standard treatment called targeted radiation therapy (PRRT). The goal is to find imaging markers that can predict who will respond best to treatment, helping doctors personalize care in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hépato-gastro-entérologie, cancérologie digestive et assistance nutritionnelle - CHU Nantes

    ACTIVE_NOT_RECRUITING

    Nantes, 44000, France

  • Médecine nucléaire - CHU Nantes

    RECRUITING

    Nantes, 44000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Médecine nucléaire et Biophysique - Beaujon

    RECRUITING

    Clichy, 92110, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Pancréatologie et Oncologie Digestive - Beaujon

    RECRUITING

    Clichy, 92110, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Service de Médecine Nucléaire, Groupe Hospitalier Bichat-Claude Bernard

    ACTIVE_NOT_RECRUITING

    Paris, 75018, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

68Ga-DOTATOC PET-MRI imaging

What this could lead to

If successful, this could lead to better ways to predict which patients will benefit most from targeted radiation therapy for GEP-NETs.

What could go wrong

This is an observational imaging study, not a treatment trial. It may not directly improve outcomes, and results may not apply to all patients.

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.